good news! The newsletter of the Department of Rheumatology and Immunology of North Guangdong People's Hospital was listed in the world's top medical journals

Recently, Dr. Xia Mao Li, Chief Physician of the Department of Rheumatology and Immunology, North Guangdong People's Hospital, and Chief Physician Wang Hai published a report entitled "Nonalcoholic Fatty Liver Disease" in the world's top medical journal The New England Journal of Medicine (NEJM; 2021 IF: 91.253) The correspondence paper (non-alcoholic fatty liver disease) marks a historic breakthrough in the scientific research construction of high-level hospitals.

In this paper, it is proposed that the quality control of histopathological results needs to be paid attention to in the trial of non-alcoholic steatohepatitis (NASH), and a methodological breakthrough is found to solve the problem of NASH new drug trial that has long plagued the medical community. This is the first time that the hospital has appeared on the world's most authoritative medical academic platform as an independent corresponding author unit and demonstrated the "Guangdong North Concept".

It is understood that the New England Journal of Medicine is a peer-reviewed medical journal published by the Massachusetts Medical Society in the United States, and it is also one of the most popular and widely read comprehensive medical journals in the world. Founded in 1811 by Dr. John Cohen, it has a long history of more than 200 years. Its academic influence ranks first among the world's top medical journals, and the research results, academic views and clinical practice content published have become the most important basis and source of the recommended content of the World Health Organization (WHO), the US Food and Drug Administration (FDA) and major medical guidelines, and are regarded as the absolute authority in the medical field.

Xia Maoli introduced that non-alcoholic fatty liver disease is one of the most common causes of chronic liver disease, of which NASH is the advanced stage of non-alcoholic fatty liver disease, which is highly correlated with adverse prognosis such as liver fibrosis, cirrhosis, and liver transplantation. However, at present, there is no clinical treatment drug for non-alcoholic fatty liver disease officially approved by the FDA, which is mainly due to the repeated failures of NASH new drug trials, which has become a major problem that has long plagued the medical community. In fact, about 25% of people in the world suffer from non-alcoholic fatty liver disease, and the number of people in China is closer to 30% (more than 400 million). The treatment of non-alcoholic fatty liver disease faces a huge clinical demand and no drug availability. Although many experts and scholars have published articles discussing the many influencing factors of the experiment, there has been no substantial progress in this difficult problem for many years.

In view of this problem, Xia Maoli has long been concerned about the progress of relevant trials, and after in-depth study of a large number of previous literature and related clinical trial protocols, it is found that the possible reasons for the failure of NASH new drug trials are numerous, but these factors are basically isolated, not every trial necessarily exists and has an impact, and after years of clinical research experience summary and iteration, the quality of the trial should be higher and higher, but there is still no breakthrough so far. After rigorous reasoning and verification, the author finally came up with new arguments and new ideas recognized by authority.

In recent years, the Department of Rheumatology and Immunology of North Guangdong People's Hospital has made great strides in the diagnosis and treatment of difficult and rare diseases in closely following the international frontier. B-cell depletion therapy (beliyumab, tetacip) for refractory lupus, JAK-STAT pathway blocking therapy (tofatibu, barretinib) against MDA5-positive dermaidositis without myopathy, and targeted therapies for psoriatic arthritis (e.g., IL-17 or TNF-a antagonists) have been effective. Next, the upcoming new technology of needle and knife mirror treatment of refractory arthropathy will strive to provide a higher level of specialized medical services for the majority of patients in northern Guangdong.

[All-media reporter] Ye Zhiqiang

【Correspondent】 He Xiujuan, Lu Yanping

【Author】

【Source】 Southern Press Media Group South + client